Publication
Abstract
Realization of a part of clinical trial called Multicenter, randomized, double-blind, active-controlled study - Phase 3 monitoring safety and efficacy of rolapitant in preventing chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC)